What is the main reason for the upward revision in Thermo Fisher's Q4 2020 guidance?

The upward revision is driven by stronger-than-expected organic revenue growth in both Thermo Fisher's established business segments and its COVID-19 response-related products and services. This indicates a robust demand environment across multiple areas of the company's operations.

How does the revised Q4 guidance compare to the company's previous outlook?

The company significantly improved its outlook, now expecting Q4 organic revenue growth of 40%, a substantial increase from the previously guided 29%. Similarly, the full-year adjusted EPS projection was raised to $19.17, reflecting 55% year-over-year growth, up from the prior expectation of 48% growth.

What are the potential risks or uncertainties associated with these updated projections?

Thermo Fisher acknowledges that actual results could differ from these estimates due to the "greater-than-normal uncertainty that continues to exist in the marketplace." Specific risk factors mentioned include the duration and severity of the COVID-19 pandemic, product development needs, economic conditions, government policies, and other factors detailed in their SEC filings.

What is 'adjusted EPS' and why does Thermo Fisher use it?

Adjusted EPS is a non-GAAP financial measure that excludes certain items such as acquisition-related costs, restructuring costs, amortization of intangible assets, and other one-time or difficult-to-forecast items. Thermo Fisher uses adjusted EPS to provide investors with a better understanding of the company's core operating performance and to facilitate comparisons with prior periods and forecasts, as management measures performance using these metrics.

TMO 8-K: Regulation FD

Summary

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on December 1, 2020, to provide an update from their CEO at the Evercore ISI HealthCONx Conference. The key takeaway for investors is a significant upward revision to their fourth-quarter 2020 outlook. The company now expects Q4 organic revenue growth of 40%, a substantial increase from the previously guided 29%, driven by stronger performance in both their base business and COVID-19 response revenue. This performance is expected to translate to full-year 2020 organic revenue growth of approximately 22% and adjusted earnings per share (EPS) of $19.17, representing 55% year-over-year growth, also exceeding prior guidance. This positive update indicates that Thermo Fisher is not only benefiting from the increased demand related to the COVID-19 pandemic but also experiencing robust underlying growth in its core operations. Investors should note that these are forward-looking estimates and are subject to the inherent uncertainties of the current market environment, as detailed in the company's cautionary statements. The company also provided clarity on its use of non-GAAP financial measures, specifically adjusted EPS, which excludes various items to better reflect core operating results.

Key Highlights

1Thermo Fisher raised its Q4 2020 organic revenue growth expectation to 40%, up from 29% previously guided.
2Full-year 2020 organic revenue growth is now projected to be approximately 22%.
3Expected full-year 2020 adjusted EPS is $19.17, representing 55% growth over 2019, an increase from prior guidance of 48% growth.
4The improved outlook is attributed to stronger performance in both the company's base business and COVID-19 response revenue.
5The company's CEO, Marc N. Casper, provided these updates during a virtual fireside chat at the Evercore ISI HealthCONx Conference.
6Management emphasizes the use of non-GAAP measures like adjusted EPS to provide a clearer view of core operating performance.

THERMO FISHER SCIENTIFIC INC. 8-K Report, Regulation FD Disclosure (Dec 1, 2020)

Summary

Key Highlights

Frequently Asked Questions